Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Morishita Jintan CoTSE:4524 66 EBITDA Margin % is 12.70% as of Mar. 2026, which is 20% above its 10-year median of 10.62. GuruFocus rates TSE:4524 with a GF Score™ of 66/100 and a GF Value™ of 円2,222.64 (Fairly Valued). The stock has 5 warning signs investors should review. Among 961 Drug Manufacturers companies, Morishita Jintan Co ranks worse than 54.11% on this metric.
Morishita Jintan Co (TSE:4524) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Morishita Jintan Co EBITDA Margin % Related Terms
Morishita Jintan Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Morishita Jintan Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Morishita Jintan Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Morishita Jintan Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Morishita Jintan Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Morishita Jintan Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Morishita Jintan Co (TSE:4524) has a EBITDA Margin % of 12.70% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Morishita Jintan Co and its competitors. This is 20% above median its historical median of 10.62. Over the past decade, Morishita Jintan Co's EBITDA Margin % has ranged from 9.03 to 12.85. According to the industry distribution chart, Morishita Jintan Co ranks #520 out of 961 companies in the Drug Manufacturers industry, placing it in the top 54.1%.
Is Morishita Jintan Co's EBITDA Margin % too high?
Morishita Jintan Co's current EBITDA Margin % of 12.70% is 20% above median its 10-year median of 10.62. Over the past 10 years, this metric has ranged from a low of 9.03 to a high of 12.85. The Drug Manufacturers industry median EBITDA Margin % is 12.49. Morishita Jintan Co's value of 12.70% is 1.7% above this industry median. Based on the distribution chart, Morishita Jintan Co ranks #520 out of 961 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Morishita Jintan Co has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Morishita Jintan Co's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Morishita Jintan Co ranks #520 out of 961 companies for EBITDA Margin %. This places Morishita Jintan Co in the lower half of its industry. The industry median EBITDA Margin % is 12.49. Morishita Jintan Co's value of 12.70% is 1.7% above this benchmark. Historically, Morishita Jintan Co's own EBITDA Margin % has ranged from 9.03 to 12.85 over the past decade. While the company's 10-year median is 10.62 vs. the industry median of 12.49, Morishita Jintan Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Morishita Jintan Co's current EBITDA Margin % of 12.70% is 1.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Morishita Jintan Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Morishita Jintan Co's current EBITDA Margin % is 12.70%, which is 20% above median its own 10-year median of 10.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Morishita Jintan Co stock overvalued right now?
Based on GuruFocus' analysis, Morishita Jintan Co (TSE:4524) is currently considered Fairly Valued. The stock's GF Value™ is 円2,222.64, compared to a current price of 円2,171.00 — trading 2.3% below its estimated fair value. The current EBITDA Margin % is 12.70%, which is 20% above median its 10-year median of 10.62 and 1.7% above the Drug Manufacturers industry median of 12.49. Morishita Jintan Co's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Morishita Jintan Co (TSE:4524), the current EBITDA Margin % is 12.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Morishita Jintan Co (TSE:4524) Overvalued in 2026?
Based on GuruFocus' analysis, Morishita Jintan Co stock appears to be undervalued.
The current stock price of 円2,171.00 is trading 2.3% below its estimated GF Value™ of 円2,222.64.
GuruFocus considers Morishita Jintan Co to be Fairly Valued.
Key valuation signals for TSE:4524:
EBITDA Margin %: 12.70% (20% above median its 10-year median of 10.62)
GF Value™: 円2,222.64 vs. price of 円2,171.00 (2.3% below fair value)
Industry Position: 1.7% above the Drug Manufacturers median (#520 of 961)
No single metric tells the full story. See the TSE:4524 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Morishita Jintan Co Ltd is engaged in the manufacturing and sale of pharmaceuticals, quasi-drugs, health foods, medical devices, and food. The company's product offerings include dietary supplements, food drinks, cosmetics, products for medical institutions, functional foods, and others.
66GF Score
Get the complete analysis for TSE:4524
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4524 has been successfully added to your 
